Skip to content

Category: X-linked retinitis pigmentosa

MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial MeiraGTx, a gene-therapy company in London and New York City, has treated its first patient in a gene-therapy clinical trial for people with X-linked retinitis pigmentosa (XLRP) caused by mutations…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Valproic Acid’s Effect Too Small in One-Year Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Valproic Acid’s Effect Too Small in One-Year Clinical Trial However, researchers identify a potentially powerful endpoint for evaluating emerging therapies in future studies. Results from a clinical trial sponsored by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI)…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest